Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Veracyte Inc
(NQ:
VCYT
)
31.94
+0.32 (+1.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
September 02, 2023
The genetic test maker is rapidly increasing test volumes.
Via
The Motley Fool
Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 29, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
August 22, 2023
From
Veracyte, Inc.
Via
Business Wire
Here's Why This Little-Known Growth Stock Is a Buy
May 22, 2023
Analysts think this genomic test maker could have major upside in the next year.
Via
The Motley Fool
Looking Into Veracyte's Return On Capital Employed
May 17, 2023
Via
Benzinga
Recap: Veracyte Q1 Earnings
May 04, 2023
Via
Benzinga
Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
August 15, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Second Quarter 2023 Financial Results
August 08, 2023
From
Veracyte, Inc.
Via
Business Wire
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
August 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
July 19, 2023
From
Veracyte, Inc.
Via
Business Wire
Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom
July 08, 2023
AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider.
Via
InvestorPlace
New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
June 20, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
June 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Market Mixes It Up With A Broad Rally
June 05, 2023
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive.
Via
Talk Markets
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
May 31, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
May 25, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
May 24, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in Upcoming Investor Conferences
May 23, 2023
From
Veracyte, Inc.
Via
Business Wire
Time To Play Small Cap Life Science Stocks
May 15, 2023
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling.
Via
Talk Markets
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
May 12, 2023
From
Veracyte, Inc.
Via
Business Wire
A New Groundbreaking Tool to Detect Colon Cancer Earlier
May 10, 2023
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This...
Via
PressReach
Exposures
Product Safety
Something Happened In Biotech Last Week
May 08, 2023
Biotech stocks were more constructive last week with some sharp moves up.
Via
Talk Markets
Veracyte Announces First Quarter 2023 Financial Results
May 04, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
May 04, 2023
From
Veracyte, Inc.
Via
Business Wire
Earnings Scheduled For May 4, 2023
May 04, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
Via
Benzinga
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
May 03, 2023
From
Veracyte, Inc.
Via
Business Wire
New Artificial Intelligence Tool Can Diagnose Colon Cancer
May 03, 2023
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and...
Via
PressReach
Topics
Artificial Intelligence
Death
Exposures
Artificial Intelligence
Death
Product Safety
Veracyte Announces Release of Inaugural ESG Report
May 03, 2023
From
Veracyte, Inc.
Via
Business Wire
Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
May 02, 2023
From
Veracyte, Inc.
Via
Business Wire
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
May 01, 2023
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.